Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data

27 Apr 2022

Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.

Snails on the athletic track moves the finish line (By Sergey Lavrentev. Shutterstock 463225937) — Novartis/BeiGene face tough competition in esophageal cancer despite positive data for tislelizumab • Source: Shutterstock

Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data

More from Immuno-oncology

More from Anticancer